**Table S1. Pearson correlation coefficients between structures DVH metrics for patients in 5FU-LCRT.**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Volume | Mean | V5 | V10 | V15 | V20 | V25 | V30 | V35 | V40 | V45 |
| Volume | 1 | -0.405 | -0.187 | -0.25 | -0.243 | -0.268 | -0.221 | -0.327 | -0.392 | -0.405 | -0.384 |
| *P*-value | 0.00394 | 0.199 | 0.0833 | 0.0924 | 0.0624 | 0.127 | 0.022 | 0.00536 | 0.00389 | 0.00646 |
| Mean | -0.405 | 1 | 0.693 | 0.54 | 0.618 | 0.791 | 0.937 | 0.848 | 0.827 | 0.786 | 0.676 |
| *P*-value | 0.00394 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V5 | -0.187 | 0.693 | 1 | 0.618 | 0.670 | 0.690 | 0.602 | 0.414 | 0.378 | 0.372 | 0.301 |
| *P*-value | 0.199 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | 0.0031 | 0.00744 | 0.0085 | 0.0354 |
| V10 | -0.25 | 0.54 | 0.618 | 1 | 0.973 | 0.808 | 0.457 | 0.054 | 0.008 | -0.035 | -0.111 |
| *P*-value | 0.0833 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | 0.715 | 0.956 | 0.812 | 0.446 |
| V15 | -0.243 | 0.618 | 0.670 | 0.973 | 1 | 0.901 | 0.562 | 0.148 | 0.091 | 0.034 | -0.074 |
| *P*-value | 0.0924 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | 0.309 | 0.535 | 0.819 | 0.612 |
| V20 | -0.268 | 0.791 | 0.690 | 0.808 | 0.901 | 1 | 0.782 | 0.412 | 0.363 | 0.298 | 0.154 |
| *P*-value | 0.0624 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | 0.00331 | 0.0104 | 0.0376 | 0.291 |
| V25 | -0.221 | 0.937 | 0.602 | 0.457 | 0.562 | 0.782 | 1 | 0.830 | 0.763 | 0.689 | 0.544 |
| *P*-value | 0.127 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V30 | -0.327 | 0.848 | 0.414 | 0.054 | 0.148 | 0.412 | 0.830 | 1 | 0.969 | 0.924 | 0.819 |
| *P*-value | 0.022 | *<*0.001 | 0.0031 | 0.715 | 0.309 | 0.00331 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V35 | -0.392 | 0.827 | 0.378 | 0.008 | 0.091 | 0.363 | 0.763 | 0.969 | 1 | 0.979 | 0.901 |
| *P*-value | 0.00536 | *<*0.001 | 0.00744 | 0.956 | 0.535 | 0.0104 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V40 | -0.405 | 0.786 | 0.372 | -0.035 | 0.034 | 0.298 | 0.689 | 0.924 | 0.979 | 1 | 0.954 |
| *P*-value | 0.00389 | *<*0.001 | 0.0085 | 0.812 | 0.819 | 0.0376 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V45 | -0.384 | 0.676 | 0.301 | -0.111 | -0.074 | 0.154 | 0.544 | 0.819 | 0.901 | 0.954 | 1 |
| *P*-value | 0.00646 | *<*0.001 | 0.0354 | 0.446 | 0.612 | 0.291 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |

Abbreviations: Vx, volume of structure that receives greater than or equal to x Gy; 5FU, 5-fluorouracil; LCRT, long-course radiotherapy with 2Gy×25; DVH, Dose-volume histogram.

**Table S2. Pearson correlation coefficients between structures DVH metrics for patients in FOLFOX-LCRT.**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Volume | Mean | V5 | V10 | V15 | V20 | V25 | V30 | V35 | V40 | V45 |
| Volume | 1 | -0.376 | -0.106 | -0.242 | -0.211 | -0.233 | -0.302 | -0.319 | -0.364 | -0.392 | -0.368 |
| *P*-value | *<*0.001 | 0.240 | 0.00652 | 0.018 | 0.00893 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| Mean | -0.376 | 1 | 0.476 | 0.588 | 0.680 | 0.794 | 0.937 | 0.869 | 0.824 | 0.767 | 0.628 |
| *P*-value | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V5 | -0.106 | 0.476 | 1 | 0.684 | 0.562 | 0.504 | 0.315 | 0.167 | 0.140 | 0.131 | 0.182 |
| *P*-value | 0.240 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | 0.0619 | 0.120 | 0.145 | 0.0427 |
| V10 | -0.242 | 0.588 | 0.684 | 1 | 0.869 | 0.709 | 0.474 | 0.207 | 0.129 | 0.0712 | -0.00926 |
| *P*-value | 0.00652 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | 0.0206 | 0.150 | 0.430 | 0.918 |
| V15 | -0.211 | 0.680 | 0.562 | 0.869 | 1 | 0.916 | 0.631 | 0.288 | 0.185 | 0.104 | 0.0483 |
| *P*-value | 0.018 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | 0.00111 | 0.0385 | 0.248 | 0.592 |
| V20 | -0.233 | 0.794 | 0.504 | 0.709 | 0.916 | 1 | 0.792 | 0.485 | 0.382 | 0.291 | 0.220 |
| *P*-value | 0.00893 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | 0.00101 | 0.0136 |
| V25 | -0.302 | 0.937 | 0.315 | 0.474 | 0.631 | 0.792 | 1 | 0.873 | 0.774 | 0.676 | 0.471 |
| *P*-value | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V30 | -0.319 | 0.869 | 0.167 | 0.207 | 0.288 | 0.485 | 0.873 | 1 | 0.966 | 0.901 | 0.656 |
| *P*-value | *<*0.001 | *<*0.001 | 0.0619 | 0.0206 | 0.00111 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V35 | -0.364 | 0.824 | 0.140 | 0.129 | 0.185 | 0.382 | 0.774 | 0.966 | 1 | 0.970 | 0.752 |
| *P*-value | *<*0.001 | *<*0.001 | 0.120 | 0.150 | 0.0385 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V40 | -0.392 | 0.767 | 0.131 | 0.0712 | 0.104 | 0.291 | 0.676 | 0.901 | 0.970 | 1 | 0.847 |
| *P*-value | *<*0.001 | *<*0.001 | 0.145 | 0.430 | 0.248 | 0.00101 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V45 | -0.368 | 0.628 | 0.182 | -0.00926 | 0.0483 | 0.220 | 0.471 | 0.656 | 0.752 | 0.847 | 1 |
| *P*-value | *<*0.001 | *<*0.001 | 0.0427 | 0.918 | 0.592 | 0.0136 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |

Abbreviations: Vx, volume of structure that receives greater than or equal to x Gy; FOLFOX, 5-fluorouracil+oxaliplatin; LCRT, long-course radiotherapy with 2Gy×25; DVH, Dose-volume histogram.

**Table S3. Pearson correlation coefficients between structures DVH metrics for patients in FOLFOX-SCRT.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Volume | Mean | V5 | V10 | V15 | V20 | V25 |
| Volume | 1 | -0.247 | -0.189 | -0.215 | -0.207 | -0.226 | -0.369 |
| *P*-value | 0.0106 | 0.0517 | 0.0269 | 0.0331 | 0.0196 | *<*0.001 |
| Mean | -0.247 | 1 | 0.881 | 0.942 | 0.969 | 0.805 | 0.807 |
| *P*-value | 0.0106 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V5 | -0.189 | 0.881 | 1 | 0.904 | 0.762 | 0.590 | 0.614 |
| *P*-value | 0.0517 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V10 | -0.215 | 0.942 | 0.904 | 1 | 0.875 | 0.656 | 0.657 |
| *P*-value | 0.0269 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V15 | -0.207 | 0.969 | 0.762 | 0.875 | 1 | 0.830 | 0.777 |
| *P*-value | 0.0331 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V20 | -0.226 | 0.805 | 0.590 | 0.656 | 0.830 | 1 | 0.761 |
| *P*-value | 0.0196 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |
| V25 | -0.369 | 0.807 | 0.614 | 0.657 | 0.777 | 0.761 | 1 |
| *P*-value | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 | *<*0.001 |

Abbreviations: Vx, volume of structure that receives greater than or equal to x Gy; FOLFOX, 5-fluorouracil+oxaliplatin; SCRT, short-course radiotherapy with 5Gy×5; DVH, Dose-volume histogram.

**Table S4. Univariate logistic regression analysis for HT2+.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 5FU-LCRT(n=49) | |  | FOLFOX-LCRT(n=125) | |  | FOLFOX-SCRT(n=106) | |
| OR (95% CI) | *P*-value |  | OR (95% CI) | *P*-value |  | OR (95% CI) | *P*-value |
| Volume (mL) | 1.00(1.00-1.00) | 0.010\* |  | 1.00(1.00-1.00) | 0.034\* |  | 1.00(1.00-1.00) | 0.455 |
| Mean (cGy) | 1.01(1.00-1.01) | <0.001\* |  | 1.00(1.00-1.01) | <0.001\* |  | 1.00(1.00-1.01) | <0.001\* |
| V5 (%) | 1.92(1.18-3.12) | 0.008\* |  | 1.04(0.95-1.15) | 0.402 |  | 1.08(1.04-1.12) | <0.001\* |
| V10 (%) | 1.05(0.97-1.13) | 0.228 |  | 1.07(1.01-1.12) | 0.019\* |  | 1.07(1.04-1.10) | <0.001\* |
| V15 (%) | 1.05(0.98-1.12) | 0.159 |  | 1.07(1.03-1.12) | 0.001\* |  | 1.08(1.05-1.12) | <0.001\* |
| V20 (%) | 1.10(1.03-1.18) | 0.007\* |  | 1.09(1.05-1.14) | <0.001\* |  | 1.10(1.06-1.14) | <0.001\* |
| V25 (%) | 1.19(1.08-1.30) | <0.001\* |  | 1.14(1.07-1.21) | <0.001\* |  | 1.20(1.11-1.30) | <0.001\* |
| V30 (%) | 1.14(1.06-1.22) | <0.001\* |  | 1.09(1.04-1.14) | <0.001\* |  | NA | NA |
| V35 (%) | 1.14(1.06-1.23) | <0.001\* |  | 1.09(1.04-1.14) | <0.001\* |  | NA | NA |
| V40 (%) | 1.17(1.08-1.28) | <0.001\* |  | 1.09(1.03-1.15) | 0.001\* |  | NA | NA |
| V45 (%) | 1.20(1.08-1.34) | 0.001\* |  | 1.06(0.98-1.14) | 0.126 |  | NA | NA |

Abbreviations: 5FU, 5-fluorouracil; FOLFOX, 5-fluorouracil+oxaliplatin; LCRT, long-courseradiotherapy with 2Gy×25; SCRT, short-course radiotherapy with 5Gy×5; OR, odds ratio; CI, confidence interval; Vx, volume of structure that receives greater than or equal to x Gy.

\*The correlations between dosimetric parameters and HT2+ event were statistically significant.

**Table S5. Multivariate logistic regression analysis for HT2+.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 5FU-LCRT(n=49) | |  | FOLFOX-LCRT(n=125) | |  | FOLFOX-SCRT(n=106) | |
| OR (95% CI) | *P*-value | OR (95% CI) | *P*-value | OR (95% CI) | *P*-value |
| Volume (mL) | 1.00(0.99-1.00) | 0.078 | Mean (cGy) | 0.98(0.97-1.00) | 0.008\* | V20 (%) | 1.10(1.06-1.14) | <0.001\* |
| V5 (%) | 3.65(1.37-9.72) | 0.010\* | V10 (%) | 1.20(1.03-1.39) | 0.018\* |  |  |  |
| V20 (%) | 0.74(0.55-1.00) | 0.047\* | V20 (%) | 1.21(1.03-1.41) | 0.019\* |  |  |  |
| V25 (%) | 1.99(1.13-3.53) | 0.018\* | V25 (%) | 1.25(1.05-1.50) | 0.011\* |  |  |  |
| V30 (%) | 0.59(0.35-1.00) | 0.048\* | V40 (%) | 1.42(1.10-1.83) | 0.007\* |  |  |  |
| V40 (%) | 1.41(1.01-1.96) | 0.046\* |  |  |  |  |  |  |

Abbreviations: 5FU, 5-fluorouracil; FOLFOX, 5-fluorouracil+oxaliplatin; LCRT, long-courseradiotherapy with 2Gy×25; SCRT, short-course radiotherapy with 5Gy×5; OR, odds ratio; CI, confidence interval; Vx, volume of structure that receives greater than or equal to x Gy.

\*The correlations between dosimetric parameters and HT3+ event were statistically significant.